Detail akcie Biolife Solutions online

Business Summary: BioLife Solutions, Inc. is a developer and supplier of cell processing tools and services for the cell and gene therapy (CGT) market. The Company facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during the collection, development, manufacturing and distribution. Its CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the cell and gene therapy market. Its Sexton cell processing product line includes human platelet lysates (hPL) for cell expansion. Its CellSeal closed systems are purpose-built rigid containers used in cell and gene therapy (CGT). Its CryoCase cryo-compatible transparent rigid containers are designed for closed-system fill and retrieval, and automated cell processing machines. The Company's ThawSTAR product line comprises a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.
Financial Summary: BRIEF: For the three months ended 31 March 2026, BioLife Solutions Inc revenues increased 25% to $27.5M. Net income before extraordinary items increased from $271K to $1.2M. Revenues reflect United States segment increase of 25% to $22M, Other Countries segment increase of 50% to $1.7M. Net income benefited from Interest Expense/Income - Net increase of 52% to $1M (income), Other income increase of 78% to $180K (income).